QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NYSE:MED

Medifast (MED) Stock Forecast, Price & News

$81.86
+1.94 (+2.43%)
(As of 06/6/2023 ET)
Compare
Today's Range
$79.00
$82.83
50-Day Range
$78.69
$103.67
52-Week Range
$77.67
$192.44
Volume
143,342 shs
Average Volume
208,542 shs
Market Capitalization
$891.46 million
P/E Ratio
6.41
Dividend Yield
8.06%
Price Target
$110.50

Medifast MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
35.0% Upside
$110.50 Price Target
Short Interest
Healthy
15.33% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-4.12
Upright™ Environmental Score
News Sentiment
0.52mentions of Medifast in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$239,096 Sold Last Quarter
Proj. Earnings Growth
10.16%
From $8.86 to $9.76 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Consumer Staples Sector

15th out of 140 stocks

Miscellaneous Food Preparations & Kindred Products Industry

1st out of 5 stocks


MED stock logo

About Medifast (NYSE:MED) Stock

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

MED Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Medifast (NYSE:MED) Stock Rating Upgraded by StockNews.com
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Medifast (NYSE:MED) Now Covered by StockNews.com
Medifast (NYSE:MED) Downgraded by StockNews.com to "Hold"
Q1 2023 Medifast Inc Earnings Call
Medifast (NYSE:MED) Raised to "Buy" at StockNews.com
Medifast (MED) to Release Quarterly Earnings on Monday
Is Medifast, Inc. (NYSE:MED) Potentially Undervalued?
See More Headlines

MED Price History

MED Company Calendar

Ex-Dividend for 5/9 Dividend
3/27/2023
Last Earnings
5/01/2023
Dividend Payable
5/09/2023
Today
6/06/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Miscellaneous food preparations & kindred products
Sub-Industry
Personal Products
CUSIP
58470H10
Employees
984
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$110.50
High Stock Price Forecast
$150.00
Low Stock Price Forecast
$71.00
Forecasted Upside/Downside
+34.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$143.57 million
Pretax Margin
11.92%

Debt

Sales & Book Value

Annual Sales
$1.60 billion
Cash Flow
$15.70 per share
Book Value
$14.19 per share

Miscellaneous

Free Float
10,637,000
Market Cap
$895.70 million
Optionable
Optionable
Beta
1.21

Key Executives

  • Daniel R. ChardDaniel R. Chard
    Executive Chairman & Chief Executive Officer
  • Anthony Tyree
    Chief Business Operations Officer
  • James P. Maloney
    Chief Financial Officer
  • Nicholas M. Johnson
    Chief Field Operations Officer
  • Jonathan B. MacKenzie
    Chief Accounting Officer & Vice President-Finance













MED Stock - Frequently Asked Questions

Should I buy or sell Medifast stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings
or view top-rated stocks.

What is Medifast's stock price forecast for 2023?

2 brokerages have issued 1 year price objectives for Medifast's shares. Their MED share price forecasts range from $71.00 to $150.00. On average, they predict the company's share price to reach $110.50 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price.
View analysts price targets for MED
or view top-rated stocks among Wall Street analysts.

How have MED shares performed in 2023?

Medifast's stock was trading at $115.35 at the beginning of 2023. Since then, MED stock has decreased by 28.7% and is now trading at $82.25.
View the best growth stocks for 2023 here
.

Are investors shorting Medifast?

Medifast saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,730,000 shares, an increase of 9.5% from the April 15th total of 1,580,000 shares. Based on an average daily trading volume, of 238,500 shares, the days-to-cover ratio is currently 7.3 days. Approximately 16.3% of the shares of the company are sold short.
View Medifast's Short Interest
.

When is Medifast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MED earnings forecast
.

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) released its quarterly earnings results on Monday, May, 1st. The specialty retailer reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $1.27. The specialty retailer earned $349 million during the quarter, compared to analyst estimates of $319.50 million. Medifast had a net margin of 9.27% and a trailing twelve-month return on equity of 106.70%. Medifast's revenue for the quarter was down 16.4% on a year-over-year basis. During the same period last year, the company posted $3.59 earnings per share.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast declared a quarterly dividend on Thursday, March 16th. Stockholders of record on Tuesday, March 28th will be paid a dividend of $1.65 per share on Tuesday, May 9th. This represents a $6.60 annualized dividend and a yield of 8.02%. The ex-dividend date is Monday, March 27th. This is an increase from the stock's previous quarterly dividend of $1.64.
Read our dividend analysis for MED
.

Is Medifast a good dividend stock?

Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 7.90%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 51.68%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MED will have a dividend payout ratio of 67.62% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MED.

What guidance has Medifast issued on next quarter's earnings?

Medifast updated its second quarter earnings guidance on Monday, May, 1st. The company provided earnings per share guidance of $1.32-$1.44 for the period, compared to the consensus EPS estimate of $2.82. The company issued revenue guidance of $250-$270 million, compared to the consensus revenue estimate of $313.20 million.

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.45%), Renaissance Technologies LLC (5.98%), State Street Corp (3.49%), Dimensional Fund Advisors LP (3.06%), Principal Financial Group Inc. (2.05%) and Geode Capital Management LLC (2.03%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends
.

How do I buy shares of Medifast?

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $82.25.

How much money does Medifast make?

Medifast (NYSE:MED) has a market capitalization of $895.70 million and generates $1.60 billion in revenue each year. The specialty retailer earns $143.57 million in net income (profit) each year or $12.77 on an earnings per share basis.

How many employees does Medifast have?

The company employs 984 workers across the globe.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for the company is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070.

This page (NYSE:MED) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -